Inventor · disambiguated record
Jian Yu
Also filed as: YU JIAN
24 granted patents·16 pending applications·83 citations·filing 2001–2024
95Inventor score
Files withCELL SIGNALING TECHNOLOGY INC17UNIV CALIFORNIA7RIKOVA KLARISA5UNIV COLUMBIA5AARON DIAMOND AIDS RES CENTER3
Top patents by PatentIndex Score
40 records- 0195US11312787B2Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasisUNIV CALIFORNIA·Filed 2019·Granted Apr 26, 2022·8 cites·20 claims
- 0295US7700339B2Gene defects and mutant ALK kinase in human solid tumorsCELL SIGNALING TECHNOLOGY INC·Filed 2007·Granted Apr 20, 2010·22 cites·15 claims
- 0392US9758591B2Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasisUNIV CALIFORNIA·Filed 2013·Granted Sep 12, 2017·16 cites·8 claims
- 0490US8481279B2Methods of treating lung cancer using inhibitors anaplastic lymphoma kinaseRIKOVA KLARISA·Filed 2012·Granted Jul 9, 2013·6 cites·24 claims
- 0590US8288102B2Gene defects and mutant ALK kinase in human solid tumorsRIKOVA KLARISA·Filed 2010·Granted Oct 16, 2012·5 cites·40 claims
- 0689US8377642B2Gene defects and mutant ALK kinase in human solid tumorsCELL SIGNALING TECHNOLOGY INC·Filed 2010·Granted Feb 19, 2013·5 cites·36 claims
- 0787US2025282888A1Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasisUNIV CALIFORNIA·Filed 2024·Application pending·0 cites
- 0886US10344096B2Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasisUNIV CALIFORNIA·Filed 2017·Granted Jul 9, 2019·4 cites·22 claims
- 0983US10913798B2Modulators of ROR1-ROR2 bindingUNIV CALIFORNIA·Filed 2016·Granted Feb 9, 2021·2 cites·14 claims
- 1083US8168383B2Gene defects and mutant ALK kinase in human solid tumorsRIKOVA KLARISA·Filed 2009·Granted May 1, 2012·5 cites·7 claims
- 1182US9523130B2Methods of treating non-small cell lung carcinoma (NSCLC)CELL SIGNALING TECHNOLOGY INC·Filed 2016·Granted Dec 20, 2016·1 cites·29 claims
- 1281US10308707B2Bispecific HIV-1-neutralizing antibodiesAARON DIAMOND AIDS RES CENTER·Filed 2017·Granted Jun 4, 2019·2 cites·5 claims
- 1380US12162950B2Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasisUNIV CALIFORNIA·Filed 2022·Granted Dec 10, 2024·0 cites·14 claims
- 1480US9988688B2Compositions for detecting mutant anaplastic lymphoma kinase in lung cancerCELL SIGNALING TECHNOLOGY INC·Filed 2015·Granted Jun 5, 2018·1 cites·15 claims
- 1580US8486645B2Gene defects and mutant ALK kinase in human solid tumorsRIKOVA KLARISA·Filed 2012·Granted Jul 16, 2013·2 cites·12 claims
- 1677US11505833B2Compositions for detecting mutant anaplastic lymphoma kinase in lung cancerCELL SIGNALING TECHNOLOGY INC·Filed 2020·Granted Nov 22, 2022·0 cites·10 claims
- 1773US10870892B2Compositions for detecting mutant anaplastic lymphoma kinase in lung cancerCELL SIGNALING TECHNOLOGY INC·Filed 2018·Granted Dec 22, 2020·0 cites·12 claims
- 1873US9587012B2Bispecific HIV-1 neutralizing antibodiesAARON DIAMOND AIDS RES CENTER·Filed 2014·Granted Mar 7, 2017·2 cites·10 claims
- 1971US9884905B2Bispecific HIV-1 neutralizing antibodiesAARON DIAMOND AIDS RES CENTER·Filed 2017·Granted Feb 6, 2018·1 cites·6 claims
- 2070US10955416B2Compositions for detecting mutant anaplastic lymphoma kinase in human lung cancerCELL SIGNALING TECHNOLOGY INC·Filed 2018·Granted Mar 23, 2021·0 cites·9 claims
- 2169US12286480B2Modulators of ROR1-ROR2 bindingUNIV CALIFORNIA·Filed 2020·Granted Apr 29, 2025·0 cites·17 claims
- 2267US2018156802A1Methods of treating lung cancer by administration of an alk inhibitorCELL SIGNALING TECHNOLOGY INC·Filed 2017·Application pending·0 cites
- 2365US2024002476A1Potent neutralizing antibodies against sars-cov-2, generation and uses thereofUNIV COLUMBIA·Filed 2021·Application pending·0 cites
- 2465US2023203134A1Potent neutralizing antibodies against sars-cov-2, generation and uses thereofUNIV COLUMBIA·Filed 2021·Application pending·0 cites
- 2565US2023203138A1Potent neutralizing antibodies against sars-cov-2, generation and uses thereofUNIV COLUMBIA·Filed 2021·Application pending·0 cites
- 2662US2014134640A1Gene Defects And Mutant ALK Kinase In Human Solid TumorsCELL SIGNALING TECHNOLOGY INC·Filed 2013·Application pending·0 cites
- 2761US2013209452A1Gene defects and mutant alk kinase in human solid tumorsRIKOVA KLARISA·Filed 2012·Application pending·0 cites
- 2860US7977462B2Tyrosine phosphorylation sitesCELL SIGNALING TECHNOLOGY INC·Filed 2008·Granted Jul 12, 2011·1 cites·2 claims
- 2959US12098187B2Bispecific HIV-1-neutralizing antibodiesUNIV COLUMBIA·Filed 2018·Granted Sep 24, 2024·0 cites·3 claims
- 3057US2024343781A1Characterization of potent and broadly neutralizing monoclonal antibodies against sars-cov-2, its variants, and related coronaviruses and methods of useUNIV COLUMBIA·Filed 2022·Application pending·0 cites
- 3155US10000568B2Compositions and methods for detecting EGFR in cancerGU TING LEI·Filed 2009·Granted Jun 19, 2018·0 cites·5 claims
- 3244US10654943B2Tri-specific antibodies for HIV therapyUNIV ROCKEFELLER·Filed 2016·Granted May 19, 2020·0 cites·8 claims
- 3344US2009305297A1Tyrosine phosphorylation sitesCELL SIGNALING TECHNOLOGY INC·Filed 2008·Application pending·0 cites
- 3443US2009053831A1Tyrosine phosphorylation sitesCELL SIGNALING TECHNOLOGY INC·Filed 2008·Application pending·0 cites
- 3543US2010093000A1Tyrosine phosphorylation sitesCELL SIGNALING TECHNOLOGY INC·Filed 2008·Application pending·0 cites
- 3643US2010120055A1Tyrosine phosphorylation sitesCELL SIGNALING TECHNOLOGY INC·Filed 2007·Application pending·0 cites
- 3743US2004077832A1Jfy1protein induces rapid apoptosisFiled 2001·Application pending·0 cites
- 3838US2011059463A1Serine and Threonine Phosphorylation SitesCELL SIGNALING TECHNOLOGY INC·Filed 2010·Application pending·0 cites
- 3936US2011143368A1Tyrosine phosphorylation sitesCELL SIGNALING TECHNOLOGY INC·Filed 2010·Application pending·0 cites
- 4032US2011045603A1Serine, Threonine, and Tyrosine Phosphorylation SitesCELL SIGNALING TECHNOLOGY INC·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Jian Yu files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →